Search

Your search keyword '"Michael, Nelson L"' showing total 1,536 results

Search Constraints

Start Over You searched for: Author "Michael, Nelson L" Remove constraint Author: "Michael, Nelson L"
1,536 results on '"Michael, Nelson L"'

Search Results

1. HIV incidence and its associated factors among young adults with multiple sexual partners in Maputo, Mozambique: a vaccine preparedness study

2. Differences in neutralizing antibody sensitivities and envelope characteristics indicate distinct antigenic properties of Nigerian HIV-1 subtype G and CRF02_AG

3. Immunogenicity of 2 therapeutic mosaic HIV-1 vaccine strategies in individuals with HIV-1 on antiretroviral therapy

4. Diverse array of neutralizing antibodies elicited upon Spike Ferritin Nanoparticle vaccination in rhesus macaques

5. SARS-CoV-2 ferritin nanoparticle vaccines produce hyperimmune equine sera with broad sarbecovirus activity

6. Clinical, molecular, and drug resistance epidemiology of HIV in Jordan, 2019-2021: A national study

7. SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial

8. SARS-CoV-2 spike-ferritin-nanoparticle adjuvanted with ALFQ induces long-lived plasma cells and cross-neutralizing antibodies

9. Antibody targeting of conserved sites of vulnerability on the SARS-CoV-2 spike receptor-binding domain

10. Tracking coreceptor switch of the transmitted/founder HIV-1 identifies co-evolution of HIV-1 antigenicity, coreceptor usage and CD4 subset targeting: the RV217 acute infection cohort study

11. Priming with Japanese encephalitis virus or yellow fever virus vaccination led to the recognition of multiple flaviviruses without boosting antibody responses induced by an inactivated Zika virus vaccine

12. Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial

13. Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study

14. Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial

15. Zika-specific neutralizing antibodies targeting inter-dimer envelope epitopes

16. Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study

17. Dynamic MAIT cell response with progressively enhanced innateness during acute HIV-1 infection.

18. Preferential and persistent impact of acute HIV-1 infection on CD4⁺ iNKT cells in colonic mucosa

19. Ad26.COV2.S and SARS-CoV-2 spike protein ferritin nanoparticle vaccine protect against SARS-CoV-2 Omicron BA.5 challenge in macaques

20. Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques

21. SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial

22. Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting

23. Dissecting drivers of immune activation in chronic HIV-1 infection

24. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study

25. Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques

26. Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques

27. Neurocognitive impact of Zika virus infection in adult rhesus macaques

28. Associations of human leukocyte antigen with neutralizing antibody titers in a tetravalent dengue vaccine phase 2 efficacy trial in Thailand

29. HLA tapasin independence : broader peptide repertoire and HIV control

30. Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations

31. Elevated HLA-A expression impairs HIV control through inhibition of NKG2A-expressing cells

32. Differential Inhibitory Receptor Expression on T Cells Delineates Functional Capacities in Chronic Viral Infection

34. The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination

35. Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adults

37. Immune correlates of protection for dengue: State of the art and research agenda

38. Preservation of Peripheral T Follicular Helper Cell Function in HIV Controllers

39. Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial

40. Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial

41. Impact of HLA class I functional divergence on HIV control

42. Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition

43. Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial

44. SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses

45. Determinants of suboptimal [CD4.sup.+] T cell recovery after antiretroviral therapy initiation in a prospective cohort of acute HIV-1 infection

46. Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound

47. Plasmacytoid dendritic cells sense HIV replication before detectable viremia following treatment interruption

48. Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor

49. Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques

50. Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research

Catalog

Books, media, physical & digital resources